Literature DB >> 21237358

[Interpersonal and social rhythm therapy (IPSRT)].

T Bottai1, M Biloa-Tang, S Christophe, C Dupuy, L Jacquesy, F Kochman, J-A Meynard, D Papeta, H Rahioui, M Adida, E Fakra, A Kaladjian, D Pringuey, J-M Azorin.   

Abstract

Bipolar disorder is common, recurrent, often severe and debiliting disorder. All types of bipolar disorder have a common determinant: depressive episode. It is justify to propose a psychotherapy which shown efficacy in depression. Howewer, perturbations in circadian rhythms have been implicated in the genesis of each episode of the illness. Biological circadian dysregulation can be encouraged by alteration of time-givers (Zeitgebers) or occurrence of time-disturbers (Zeitstörers). Addition of social rhythm therapy to interpersonal psychotherapy leads to create a new psychotherapy adaptated to bipolar disorders: InterPersonal and Social Rhythm Therapy (IPSRT). IPSRT, in combinaison with medication, has demonstrated efficacy as a treatment for bipolar disorders. IPSRT combines psychoeducation, behavioral strategy to regularize daily routines and interpersonal psychotherapy which help patients cope better with the multiple psychosocial and relationship problems associated with this chronic disorder. The main issues of this psychotherapy are: to take the history of the patient's illness and review of medication, to help patient for "grief for the lost healthy self" translated in the french version in "acceptance of a long-term medical condition", to give the sick role, to examinate the current relationships and changes proximal to the emergence of mood symptoms in the four problem areas (unresolved grief, interpersonal disputes, role transitions, role déficits), to examinate and increase daily routines and social rhythms. French version of IPSRT called TIPARS (with few differences), a time-limited psychotherapy, in 24 sessions during approximatively 6 months, is conducted in three phases. In the initial phase, the therapist takes a thorough history of previous episodes and their interpersonal context and a review of previous medication, provides psychoeducation, evaluates social rhythms, introduces the Social Rhythm Metric, identifies the patient's main interpersonal problem area, and contractualizes the therapy. In the second phase, the therapist focuses work with patient toward regulating the patient's daily routines as well as resolving the interpersonal problem areas relevant to episodes (mainly interpersonal disputes and role transitions). In the third or terminaison phase, the therapist evaluates efficacy of the therapy, enhances the patient's independent functioning and develops strategies for relapse prevention. The further maintenance phase suggests differents strategies as maintenance therapy or focused intensive interventions on specific topics. Copyright Â
© 2010 L'Encéphale. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21237358     DOI: 10.1016/S0013-7006(10)70059-2

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  3 in total

1.  Potential Mechanisms of COVID-19-Related Psychological Problems and Mental Disorders.

Authors:  Alfred Shaw
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Validation of the English version of the Mood Rhythm Instrument.

Authors:  Melissa A B Oliveira; Kristina Epifano; Salina Mathur; Felipe Gutiérrez Carvalho; Marina Scop; Alicia Carissimi; Ana Paula Francisco; Luciene L S Garay; Ana Adan; Maria Paz Hidalgo; Benicio N Frey
Journal:  BMC Psychol       Date:  2020-04-17

3.  Living With Bipolar Disorder in the Time of Covid-19: Biorhythms During the Severe Lockdown in Cagliari, Italy, and the Moderate Lockdown in Tunis, Tunisia.

Authors:  Mauro Giovanni Carta; Uta Ouali; Alessandra Perra; Azza Ben Cheikh Ahmed; Laura Boe; Amina Aissa; Stefano Lorrai; Giulia Cossu; Alessandro Aresti; Antonio Preti; Fethi Nacef
Journal:  Front Psychiatry       Date:  2021-02-24       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.